|
π
|
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
21 auth.
S. Swindells,
T. Lutz,
L. van Zyl,
N. Porteiro,
M. Stoll,
E. Mitha,
A. Shon,
P. Benn,
Jenny Huang,
Conn M. Harrington,
...
K. Hove,
S. Ford,
C. Talarico,
V. Chounta,
H. Crauwels,
R. V. Van Solingen-Ristea,
S. Vanveggel,
D. Margolis,
Kimberly Smith,
Kati Vandermeulen,
W. Spreen
|
5 |
2021 |
5
π
|
|
π¬
|
Pharmacokinetic drug interactions of integrase strand transfer inhibitors
ChiβHua Lu,
E. Bednarczyk,
Linda M. Catanzaro,
A. Shon,
Jia-Chen Xu,
Q. Ma
|
4 |
2021 |
4
π¬
|
|
π
|
Development of new antiatherosclerotic and antithrombotic drugs utilizing F11 receptor (F11R/JAMβA) peptides
8 auth.
A. BabiΕska,
Cristina C. Clement,
M. Swiatkowska,
J. SzymaΕski,
A. Shon,
Y. Ehrlich,
...
E. Kornecki,
M. Salifu
|
3 |
2014 |
3
π
|
|
π
|
Prevalence of Transmitted HIV-1 Drug Resistance (TDR) Associated Mutations and Predicted Drug Sensitivity in Newly Diagnosed HIV-1 Patient Cohort in a Western New York, 2005-2011
8 auth.
Lili Dai,
S. Mahajan,
D. Sykes,
A. Shon,
S. Schwartz,
Ning Li,
...
Hao Wu,
C. Hsiao
|
2 |
2014 |
2
π
|
|
π
|
Antibody dependent cell cytotoxicity is maintained by the unmutated common ancestor of 6F5, a Gp41 conformational epitope targeting antibody that utilizes heavy chain VH1-2.
10 auth.
B. Wrotniak,
M. Garrett,
S. Baron,
H. Sojar,
A. Shon,
Elizabeth Asiago-Reddy,
...
J. Yager,
Spyros A. Kalams,
Michael Croix,
M. Hicar
|
1 |
2022 |
1
π
|
|
π
|
The unmutated common ancestor of Gp41 conformational epitope targeting variable heavy chain 1-02 utilizing antibodies maintains antibody dependent cell cytotoxicity
10 auth.
B. Wrotniak,
M. Garrett,
S. Baron,
H. Sojar,
A. Shon,
Elizabeth Asiago-Reddy,
...
J. Yager,
Spyros A. Kalams,
Michael Croix,
M. Hicar
|
0 |
2021 |
0
π
|
